

Fleqsuvy[®] (baclofen) – First-time authorized brand alternative

- On April 19, 2023, Wilshire launched an authorized brand alternative of Azurity's [Fleqsuvy \(baclofen\)](#) oral suspension.
- Fleqsuvy is approved for the treatment of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity.
- Oral baclofen is also available generically as a [tablet](#) and oral [solution](#), and as brand oral granules ([Lyvispah[®]](#)). These formulations carry the same indication as Fleqsuvy.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews[®] is published by the Optum Rx Clinical Services Department.